Skip to main content
JAMA Network logoLink to JAMA Network
. 2018 Feb 12;75(2):260. doi: 10.1001/jamaneurol.2017.4984

Incorrect Conflicts of Interest Disclosures

PMCID: PMC6325962  PMID: 29228075

In the Original Investigation titled “Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial,”1 published online December 18, 2017, there were errors in the Conflict of Interest Disclosures. The first sentence for Dr Dodick should have read “Dr Dodick has received compensation from serving on advisory boards and/or consulting….” instead of “Dr Dodick has served, without compensation, on advisory boards and/or has consulted….” Also, entities with which Dr Dodick is associated via advisory boards and consulting agreements were missing from the list and have been added. This article has been corrected online.

Reference

  • 1.Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial [published online December 18, 2017]. JAMA Neurol. doi: 10.1001/jamaneurol.2017.3859 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Neurology are provided here courtesy of American Medical Association

RESOURCES